Reference : Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congest...
Scientific journals : Article
Life sciences : Veterinary medicine & animal health
http://hdl.handle.net/2268/105614
Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs
English
Schuller, S. [ > > ]
Van Israël, N. [ > > ]
Vanbelle, S. [ > > ]
Clercx, Cécile mailto [Université de Liège - ULg > Département clinique des animaux de compagnie et des équidés > Pathologie médicale des petits animaux >]
Mc Entee, Kathleen mailto [Université de Liège - ULg > Département clinique des animaux de compagnie et des équidés > Pathologie médicale des petits animaux >]
2011
Journal of Veterinary Pharmacology & Therapeutics
Blackwell Publishing
322-331
Yes (verified by ORBi)
International
0140-7783
1365-2885
[en] Aldosterone plays an important role in the pathophysiology of heart failure. Aldosterone receptor blockade has been shown to reduce morbidity and mortality in human patients with advanced congestive left ventricular heart failure. This study was designed to assess the efficacy and tolerance of long-term low-dose spironolactone when added to conventional heart failure treatment in dogs with advanced heart failure. Eighteen client-owned dogs with advanced congestive heart failure due to either degenerative valve disease (n=11) or dilated cardiomyopathy (n=7) were included in this prospective, placebo-controlled, double-blinded, randomized clinical study. After initial stabilization including furosemide, angiotensin-converting enzyme inhibitors, pimobendan and digoxin, spironolactone at a median dose of 0.52 mg/kg (range 0.49-0.8 mg/kg) once daily (n=9) or placebo (n=9) was added to the treatment, and the dogs were reassessed 3 and 6 months later. Clinical scoring, echocardiography, electrocardiogram, systolic blood pressure measurement, thoracic radiography, sodium, potassium, urea, creatinine, alanine aminotransferase, aldosterone and aminoterminal atrial natriuretic propeptide were assessed at baseline, 3 and 6 months. Survival times were not significantly different between the two treatment groups. Spironolactone was well tolerated when combined with conventional heart failure treatment.
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/105614

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Lack of efficacy of low-dose spironolactone as adjunct treatment to.pdfPublisher postprint221.38 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.